Literature DB >> 22072746

Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

Ritu R Bradley1, Lori F Maxfield, Diana M Lynch, Mark J Iampietro, Erica N Borducchi, Dan H Barouch.   

Abstract

The immunogenicity of adenovirus serotype 5 (Ad5) vectors has been shown to be suppressed by neutralizing antibodies (NAbs) directed primarily against the hexon hypervariable regions (HVRs). We previously reported that replacing all seven HVRs with those from the rare serotype virus Ad48 resulted in a chimeric Ad5HVR48(1-7) vector that largely evaded preexisting Ad5 immunity in mice and rhesus monkeys. In this study, we evaluated the extent to which Ad5-specific NAbs are directed against various HVRs. We constructed partial HVR-chimeric Ad5 vectors with only a subset of HVRs exchanged, and we utilized these vectors in both NAb assays and murine immunogenicity studies with and without baseline Ad5 immunity. Our results demonstrate that Ad5-specific NAbs target multiple HVRs, suggesting that replacing all HVRs is required to optimize evasion of anti-Ad5 immunity. These data have important implications for the development of novel vectors for both vaccines and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072746      PMCID: PMC3255845          DOI: 10.1128/JVI.06165-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 2.  Adenovirus structure.

Authors:  John J Rux; Roger M Burnett
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

3.  Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein.

Authors:  L K Crawford-Miksza; D P Schnurr
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

4.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

5.  Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.

Authors:  Shawn M Sumida; Diana M Truitt; Angelique A C Lemckert; Ronald Vogels; Jerome H H V Custers; Marylyn M Addo; Shahin Lockman; Trevor Peter; Fred W Peyerl; Michael G Kishko; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Myron Essex; Bruce D Walker; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch
Journal:  J Immunol       Date:  2005-06-01       Impact factor: 5.422

6.  Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

Authors:  H Gahéry-Ségard; F Farace; D Godfrin; J Gaston; R Lengagne; T Tursz; P Boulanger; J G Guillet
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.

Authors:  Shinya Abe; Kenji Okuda; Takehiro Ura; Asami Kondo; Atsushi Yoshida; Shinji Yoshizaki; Hiroyuki Mizuguchi; Dennis Klinman; Masaru Shimada
Journal:  J Gene Med       Date:  2009-07       Impact factor: 4.565

Review 9.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.

Authors:  John W Shiver; Emilio A Emini
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

10.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Ling Xu; Zhi-Yong Yang; Mario Roederer; Richard A Koup; Peter B Jahrling; Gary J Nabel
Journal:  Nature       Date:  2003-08-07       Impact factor: 49.962

View more
  46 in total

1.  Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.

Authors:  Joseph T Bruder; Ping Chen; Elena Semenova; Charlie A Thomas; Svetlana Konovalova; Greg Ekberg; Damodar Ettyreddy; Duncan McVey; Jason G Gall; C Richter King; Douglas E Brough
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

2.  Antigenic variability among two subtypes of human adenovirus serotype 7.

Authors:  Xingui Tian; Xiaobo Su; Chunyan Xue; Xiao Li; Zhichao Zhou; Rong Zhou
Journal:  Virus Genes       Date:  2014-04-24       Impact factor: 2.332

3.  Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment.

Authors:  Julian Scherer; Richard B Vallee
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

4.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

5.  Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.

Authors:  Hongling Qiu; Xiao Li; Xingui Tian; Zhichao Zhou; Ke Xing; Haitao Li; Ni Tang; Wenkuan Liu; Peisheng Bai; Rong Zhou
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 6.  In Vivo Hematopoietic Stem Cell Transduction.

Authors:  Maximilian Richter; Daniel Stone; Carol Miao; Olivier Humbert; Hans-Peter Kiem; Thalia Papayannopoulou; André Lieber
Journal:  Hematol Oncol Clin North Am       Date:  2017-10       Impact factor: 3.722

7.  Molecular evolution of human adenovirus type 16 through multiple recombination events.

Authors:  Xingui Tian; Hongkai Wu; Rong Zhou
Journal:  Virus Genes       Date:  2019-08-05       Impact factor: 2.332

8.  Germline mutations and blood malignancy (Review).

Authors:  Yuping Gong; Jili Deng; Xia Wu
Journal:  Oncol Rep       Date:  2020-11-11       Impact factor: 3.906

Review 9.  New viruses for cancer therapy: meeting clinical needs.

Authors:  Tanner S Miest; Roberto Cattaneo
Journal:  Nat Rev Microbiol       Date:  2013-12-02       Impact factor: 60.633

10.  Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.

Authors:  Aziz Alami Chentoufi; Xavier Dervillez; Pierre-Alain Rubbo; Tiffany Kuo; Xiuli Zhang; Nicolas Nagot; Edouard Tuaillon; Philippe Van De Perre; Anthony B Nesburn; Lbachir Benmohamed
Journal:  Curr Trends Immunol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.